<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890823</url>
  </required_header>
  <id_info>
    <org_study_id>RA58/075</org_study_id>
    <nct_id>NCT02890823</nct_id>
  </id_info>
  <brief_title>Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D</brief_title>
  <official_title>EFFECT OF THREE DIFFERENT DOSES OF ORAL CHOLECALCIFEROL (1000 IU, 3000 IU AND 6000 IU DAILY) ON SERUM 25-HYDROXYVITAMIN D CHANGES AMONG EPILEPSY PATIENTS WITH HYPOVITAMINOSIS D: A RANDOMIZED PROSPECTIVE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the effect of three different doses of vitamin D3 supplementation on serum
      25-hydroxyvitamin D (25(OH)D) changes in epilepsy patients receiving enzyme-inducing
      antiepileptic drugs (EIAEDs) versus patients receiving non enzyme-inducing antiepileptic
      drugs (non-EIAEDs), and to determine the prevalence of and risk factors for hypovitaminosis D
      among Thai patients with epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-blinded prospective, randomized study undertaken at epilepsy clinic of King
      Chulalongkorn Memorial Hospital. The patients with hypovitaminosis D were included and
      divided into two groups according to the type of AEDs use. Patients receiving each AEDs type
      were randomly assigned to receive vitamin D3 1000, 3000 or 6000 IU once daily. The mean
      increment in serum 25(OH)D levels were measured at 8 and 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum 25-hydroxyvitamin D changes in patients who received enzyme-inducing antiepileptic drugs (EIAEDs) versus patients receiving non enzyme-inducing antiepileptic drugs (non-EIAEDs) at the same dosage of cholecalciferal</measure>
    <time_frame>8 and 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (percentage) of the patients who have serum 25-hydroxyvitamin D levels more than 30ng/ml</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>EIAEDs-1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EIAEDs-3000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EIAEDs-6000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-EIAEDs-1000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-EIAEDs-3000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-EIAEDs-6000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <arm_group_label>EIAEDs-1000</arm_group_label>
    <arm_group_label>EIAEDs-3000</arm_group_label>
    <arm_group_label>EIAEDs-6000</arm_group_label>
    <arm_group_label>non-EIAEDs-1000</arm_group_label>
    <arm_group_label>non-EIAEDs-3000</arm_group_label>
    <arm_group_label>non-EIAEDs-6000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epilepsy patients, age â‰¥ 15 years, BMI18 - 30 kg/m2

          -  Being treated with either enzyme inducing antiepileptic drugs (EIAEDs: phenytoin,
             phenobarbital, carbamazepine and topiramate) or non-enzyme inducing antiepileptic
             drugs (Non-EIAEDs: sodium valproate, levetiracetam, and lamotrigine) at a stable
             dosage regimen for at least a year.

          -  Serum 25(OH)D &lt;30ng/ml

        Exclusion Criteria:

          -  Patients with a history of hypercalcemia, nephrolithiasis, fractures, hepatic disease,
             kidney disease, granulomatous disease or currently supplemented with vitamin D.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiepileptic Drugs</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Asian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

